ZA942251B - Protein formulation. - Google Patents

Protein formulation.

Info

Publication number
ZA942251B
ZA942251B ZA942251A ZA942251A ZA942251B ZA 942251 B ZA942251 B ZA 942251B ZA 942251 A ZA942251 A ZA 942251A ZA 942251 A ZA942251 A ZA 942251A ZA 942251 B ZA942251 B ZA 942251B
Authority
ZA
South Africa
Prior art keywords
factor viii
pct
aqueous solution
present
activity
Prior art date
Application number
ZA942251A
Other languages
English (en)
Inventor
Thomas Oesterberg
Angelica Fatouros
Original Assignee
Kabi Pharmacia Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kabi Pharmacia Ab filed Critical Kabi Pharmacia Ab
Publication of ZA942251B publication Critical patent/ZA942251B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ZA942251A 1993-05-07 1994-04-02 Protein formulation. ZA942251B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE19939301581A SE9301581D0 (sv) 1993-05-07 1993-05-07 Protein formulation

Publications (1)

Publication Number Publication Date
ZA942251B true ZA942251B (en) 1994-11-01

Family

ID=20389868

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA942251A ZA942251B (en) 1993-05-07 1994-04-02 Protein formulation.

Country Status (24)

Country Link
US (1) US5962650A (de)
EP (1) EP0700299B1 (de)
JP (1) JP3751633B2 (de)
KR (1) KR100304143B1 (de)
CN (1) CN1113655C (de)
AT (1) ATE218354T1 (de)
AU (1) AU681883B2 (de)
CA (1) CA2161350C (de)
CZ (1) CZ293527B6 (de)
DE (1) DE69430745T2 (de)
DK (1) DK0700299T3 (de)
EE (1) EE03118B1 (de)
ES (1) ES2177579T3 (de)
FI (1) FI111910B (de)
HU (1) HU215263B (de)
NO (1) NO321769B1 (de)
NZ (1) NZ266031A (de)
PL (1) PL174866B1 (de)
PT (1) PT700299E (de)
RU (1) RU2142290C1 (de)
SE (1) SE9301581D0 (de)
SK (1) SK283002B6 (de)
WO (1) WO1994026286A1 (de)
ZA (1) ZA942251B (de)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE504074C2 (sv) * 1993-07-05 1996-11-04 Pharmacia Ab Proteinberedning för subkutan, intramuskulär eller intradermal administrering
IL113010A0 (en) * 1994-03-31 1995-10-31 Pharmacia Ab Pharmaceutical formulation comprising factor VIII or factor ix with an activity of at least 200 IU/ml and an enhancer for improved subcutaneous intramuscular or intradermal administration
SE9403915D0 (sv) * 1994-11-14 1994-11-14 Annelie Almstedt Process A
SE9501189D0 (sv) * 1995-03-31 1995-03-31 Pharmacia Ab Protein formulation
US5929031A (en) * 1995-05-02 1999-07-27 Baxter Biotech Technology Sarl Storage stable hemoglobin solutions
US5925738A (en) * 1995-12-01 1999-07-20 The American National Red Cross Methods of production and use of liquid formulations of plasma proteins
US7560107B2 (en) * 1996-06-26 2009-07-14 Emory University Modified factor VIII
US5763401A (en) * 1996-07-12 1998-06-09 Bayer Corporation Stabilized albumin-free recombinant factor VIII preparation having a low sugar content
EP2921180B1 (de) * 1999-02-22 2019-08-14 University of Connecticut Albuminfreie Faktor-VIII-Formulierungen
DK1194161T3 (da) * 1999-07-13 2006-02-13 Biovitrum Ab Stabile faktor VIII-sammensatninger
JP3466516B2 (ja) * 1999-09-07 2003-11-10 科学技術振興事業団 安定保存可能な酸素輸液剤
EP1458407A1 (de) * 2001-12-21 2004-09-22 Novo Nordisk A/S Flüssige zusammensetzung von modifizierten faktor-vii-polypeptiden
AU2002351756A1 (en) 2001-12-21 2003-07-15 Novo Nordisk Health Care Ag Liquid composition of factor vii polypeptides
GB0207092D0 (en) 2002-03-26 2002-05-08 Sod Conseils Rech Applic Stable pharmaceutical composition containing factor VIII
US20040009918A1 (en) * 2002-05-03 2004-01-15 Hanne Nedergaard Stabilised solid compositions of modified factor VII
PT1517698E (pt) 2002-06-21 2014-11-19 Novo Nordisk Healthcare Ag Composições sólidas estabilizadas de polipéptidos do fator viia
US7897734B2 (en) 2003-03-26 2011-03-01 Novo Nordisk Healthcare Ag Method for the production of proteins
KR20060015574A (ko) 2003-05-23 2006-02-17 노보 노르디스크 헬스 케어 악티엔게젤샤프트 용액 중 단백질 안정화
WO2004112828A1 (en) * 2003-06-25 2004-12-29 Novo Nordisk Health Care Ag Liquid composition of factor vii polypeptides
EP1644030B1 (de) * 2003-07-01 2009-10-28 Novo Nordisk Health Care AG Flüssige wässrige pharmazeutische zusammnesetzung von factor vii polypeptiden
ES2574581T3 (es) 2003-08-14 2016-06-20 Novo Nordisk Health Care Ag Composición farmacéutica líquida acuosa de polipéptidos de tipo Factor VII
RU2373953C2 (ru) * 2003-12-19 2009-11-27 Ново Нордиск Хелс Кеа Аг Стабилизированная композиция, содержащая полипептид фактора vii
SI1750733T1 (sl) * 2004-05-03 2014-03-31 Emory University POSTOPEK DAJANJA PRAĹ IÄŚJEGA fVIII BREZ DOMENE B
US7504377B2 (en) 2006-10-23 2009-03-17 Ikor, Inc. Nitric oxide-blocked cross-linked tetrameric hemoglobin
US7494974B2 (en) 2006-10-24 2009-02-24 Ikor, Inc. Carboxymethylated cross-linked tetrameric hemoglobin
EP1982731B1 (de) * 2007-04-17 2010-06-16 Dr. Willmar Schwabe GmbH & Co. KG Verfahren zur Herstellung von lagerstabilen Lösungen aus Pelargonium-Extrakten
US8399620B2 (en) * 2007-07-11 2013-03-19 Novo Nordisk A/S Purification of factor VIII using a mixed-mode or multimodal resin
EP2113564A1 (de) 2008-05-01 2009-11-04 Arecor Limited Proteinformulierung
CN102119172A (zh) 2008-08-21 2011-07-06 奥克塔法马股份有限公司 重组制备的人类因子viii和ix
US20110178019A1 (en) * 2008-09-03 2011-07-21 Brita Rippner New protecting compositions for recombinantly produced factor viii
NZ593190A (en) 2008-11-07 2013-01-25 Baxter Int Factor viii formulations
US10172949B2 (en) 2009-06-09 2019-01-08 Prolong Pharmaceuticals, LLC Hemoglobin compositions
US10172950B2 (en) 2009-06-09 2019-01-08 Prolong Pharmaceuticals, LLC Hemoglobin compositions
KR102170375B1 (ko) * 2009-06-09 2020-10-27 프로롱 파마슈티컬스, 엘엘씨 헤모글로빈 조성물
GB0915480D0 (en) * 2009-09-04 2009-10-07 Arecor Ltd Stable formulation of factor viii
US9199016B2 (en) 2009-10-12 2015-12-01 New Health Sciences, Inc. System for extended storage of red blood cells and methods of use
US12089589B2 (en) 2009-10-12 2024-09-17 Hemanext Inc. Irradiation of red blood cells and anaerobic storage
US11284616B2 (en) 2010-05-05 2022-03-29 Hemanext Inc. Irradiation of red blood cells and anaerobic storage
ES2959120T3 (es) 2010-08-25 2024-02-20 Hemanext Inc Método para potenciar la calidad y la supervivencia de glóbulos rojos durante el almacenamiento
PT2635114T (pt) 2010-11-05 2020-06-16 New Health Sciences Inc Irradiação de glóbulos vermelhos e armazenamento anaeróbico
JP5922141B2 (ja) 2010-11-05 2016-05-24 バクスター・インターナショナル・インコーポレイテッドＢａｘｔｅｒ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｉｎｃｏｒｐ０Ｒａｔｅｄ 増加した比活性を有する抗血友病第ｖｉｉｉ因子の新規変異体
US9067004B2 (en) 2011-03-28 2015-06-30 New Health Sciences, Inc. Method and system for removing oxygen and carbon dioxide during red cell blood processing using an inert carrier gas and manifold assembly
AU2012294269B2 (en) 2011-08-10 2016-11-24 Hemanext Inc. Integrated leukocyte, oxygen and/or CO2 depletion, and plasma separation filter device
EP2961269B1 (de) 2013-02-28 2021-09-15 Hemanext Inc. Vorrichtung zur gasabreicherung für blutprodukte
ES2524516B1 (es) * 2014-05-29 2015-03-31 Grifols Worldwide Operations Limited Procedimiento de preparación de albúmina humana con nivel de oxígeno disuelto reducido
KR102701691B1 (ko) 2015-03-10 2024-08-30 헤마넥스트 인코포레이티드 산소 감소 1회용 키트, 장치 및 이의 사용 방법
KR20250126858A (ko) 2015-04-23 2025-08-25 헤마넥스트 인코포레이티드 혐기성 혈액 저장 용기
IL289099B2 (en) 2015-05-18 2024-04-01 Hemanext Inc Methods for the storage of whole blood, and compositions thereof
MX393877B (es) 2016-05-27 2025-03-24 Hemanext Inc Almacenamiento anaerobico de sangre y metodo de inactivacion de patogenos
US20210283238A1 (en) 2018-08-07 2021-09-16 Glaxosmithkline Biologicals Sa Novel processes and vaccines

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2896381A (en) * 1954-05-27 1959-07-28 Hodes Lange Corp Method and apparatus for treating and filling ampoules
US3143471A (en) * 1962-01-18 1964-08-04 Merck & Co Inc Argon method of drying and preserving lyophilized therapeutic products
US4165370A (en) * 1976-05-21 1979-08-21 Coval M L Injectable gamma globulin
US4783441A (en) * 1979-04-30 1988-11-08 Hoechst Aktiengesellschaft Aqueous protein solutions stable to denaturation
EP0081482A1 (de) * 1981-06-18 1983-06-22 E. G. Birger Blombäck Verfahren zur reinigung und konzentration des faktor-viii-komplexes
DE3144705C2 (de) * 1981-11-11 1983-12-08 Biotest-Serum-Institut Gmbh, 6000 Frankfurt Verfahren zur Herstellung eines lagerstabilen, vernetzten Hämoglobinpräparates mit hoher Sauerstoff-Transportkapazität, sowie das nach diesem Verfahren hergestellte Hämoglobinpräparat
US4481189A (en) * 1982-04-14 1984-11-06 New York Blood Center Inc. Process for preparing sterilized plasma and plasma derivatives
US4727027A (en) * 1983-05-02 1988-02-23 Diamond Scientific Co. Photochemical decontamination treatment of whole blood or blood components
US4597966A (en) * 1985-01-09 1986-07-01 Ortho Diagnostic Systems, Inc. Histidine stabilized immunoglobulin and method of preparation
EP0212040B1 (de) * 1985-08-05 1990-05-23 IMMUNO Aktiengesellschaft für chemisch-medizinische Produkte Verfahren zur Herstellung von Präparationen auf Basis von Blutgerinnungsfaktoren
US4709819A (en) * 1986-07-23 1987-12-01 Environmental Diagnostics, Inc. Method for preserving plated media and product
CA1292686C (en) * 1986-10-27 1991-12-03 Ze'ev Shaked Pharmaceutical compositions of recombinant interleukin-2 and formulation process
CA1329760C (en) * 1987-10-29 1994-05-24 Ted C. K. Lee Plasma and recombinant protein formulations in high ionic strength media
US4877608A (en) * 1987-11-09 1989-10-31 Rorer Pharmaceutical Corporation Pharmaceutical plasma protein formulations in low ionic strength media
DK18288D0 (da) * 1988-01-15 1988-01-15 Nordisk Gentofte Fremgangsmaade til pasteurisering af vandige oploesninger af faktor viii
GB8808810D0 (en) * 1988-04-14 1988-05-18 Biopharm Clinical Research Ltd Heparin-containing formulations
FR2630115B1 (fr) * 1988-04-14 1994-10-28 Merieux Inst Procede de stabilisation des solutions d'albumine humaine et solution obtenue
US5096885A (en) * 1988-04-15 1992-03-17 Genentech, Inc. Human growth hormone formulation
SE465222C5 (sv) * 1989-12-15 1998-02-10 Pharmacia & Upjohn Ab Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning
TW211015B (de) * 1990-01-11 1993-08-11 Nippon Shinyaku Co Ltd
DE4001451A1 (de) * 1990-01-19 1991-08-01 Octapharma Ag Stabile injizierbare loesungen von faktor viii und faktor ix
DE4111393A1 (de) * 1991-04-09 1992-10-15 Behringwerke Ag Stabilisierte faktor viii-praeparationen
ES2181800T3 (es) * 1994-10-31 2003-03-01 Kimberly Clark Co Medio filtrante no tejido, de alta densidad.

Also Published As

Publication number Publication date
PL311567A1 (en) 1996-02-19
EE03118B1 (et) 1998-10-15
JP3751633B2 (ja) 2006-03-01
NZ266031A (en) 1997-04-24
FI955305A0 (fi) 1995-11-06
HUT73693A (en) 1996-09-30
KR100304143B1 (ko) 2001-11-22
DK0700299T3 (da) 2002-09-23
RU2142290C1 (ru) 1999-12-10
EP0700299A1 (de) 1996-03-13
CA2161350A1 (en) 1994-11-24
JPH08509745A (ja) 1996-10-15
CA2161350C (en) 2007-10-30
AU681883B2 (en) 1997-09-11
CZ293527B6 (cs) 2004-05-12
KR960702317A (ko) 1996-04-27
DE69430745T2 (de) 2002-10-17
AU6659794A (en) 1994-12-12
PT700299E (pt) 2002-11-29
HU9503171D0 (en) 1996-01-29
FI111910B (fi) 2003-10-15
CZ286995A3 (en) 1996-05-15
NO954457L (no) 1995-11-07
NO321769B1 (no) 2006-07-03
SK138395A3 (en) 1997-02-05
EP0700299B1 (de) 2002-06-05
WO1994026286A1 (en) 1994-11-24
CN1122573A (zh) 1996-05-15
ES2177579T3 (es) 2002-12-16
DE69430745D1 (de) 2002-07-11
SK283002B6 (sk) 2003-01-09
ATE218354T1 (de) 2002-06-15
CN1113655C (zh) 2003-07-09
FI955305L (fi) 1995-11-06
PL174866B1 (pl) 1998-09-30
NO954457D0 (no) 1995-11-07
US5962650A (en) 1999-10-05
HU215263B (hu) 1998-11-30
SE9301581D0 (sv) 1993-05-07

Similar Documents

Publication Publication Date Title
ZA942251B (en) Protein formulation.
BR9607922A (pt) Produto medicamentoso final de uma proteína de plasma processos para preparar o produto medicamentoso final para melhorar a estabilidade de longo prazo de uma proteína de plasma e para tratar hemofilia e uso de um produto medicamentoso final
Pfister et al. Ascorbic acid in the treatment of alkali burns of the eye
CA1158551A (en) Plasminogen preparations
ATE73671T1 (de) Verfahren zur herstellung einer loesung hoher spezifischer volumenaktivitaet von einem protein mit gewebe-plasminogenaktivator (t-pa)-aktivitaet, loesung, enthaltend protein mit t-pa-aktivitaet und verwendung der loesung in der human- und veterinaermedizin.
ATE147945T1 (de) Verfahren zur herstellung von nahrungsmitteln und getränken
HU9302893D0 (en) Macromolecule-extract with bacterium, method for producing it and pharmaceutical products containing it
PL320342A1 (en) Thrombin inhibitor containing infusion solution, stable during storage
CA2067371A1 (en) Stable hemoglobin based composition and method to store same
SE9402119D0 (sv) Solution
ATE66147T1 (de) Verwendung von pteridinen und/oder purinen oder eines xanthinoxidase-hemmers zur herstellung eines arzneimittels zur behandlung von genetisch bedingten degenerativen netzhauterkrankungen.
IL112236A (en) Process for minimizing degradation of activated protein c
HUT60133A (en) Process for producing protein-based pharmaceutical composition having t-pa-activity and suitable for treating blood clots
TH19245A (th) วิธีป้องกันการสลายของโปรตีนซี